87 research outputs found

    The determination of acetaminophen using a carbon nanotube: graphite-based electrode

    Get PDF
    The oxidation of acetaminophen was studied at a glassy carbon electrode modified with multi-walled carbon nanotubes and a graphite paste. Cyclic voltammety, differential pulse voltammetry and square wave voltammetry at various pH values, scan rates, and the effect of the ratio of nanotubes to graphite were investigated in order to optimize the parameters for the determination of acetaminophen. Square wave voltammetry is the most appropriate technique in giving a characteristic peak at 0.52 V at pH 5. The porous nanostructure of the electrode improves the surface area which results in an increase in the peak current. The voltammetric response is linear in the range between 75 and 2000 ng.mL−1, with standard deviations between 0.25 and 7.8%, and a limit of detection of 25 ng.mL−1. The method has been successfully applied to the analysis of acetaminophen in tablets and biological fluids

    Approximate Traveling Wave Solutions of Coupled Whitham-Broer-Kaup Shallow Water Equations by Homotopy Analysis Method

    No full text
    The homotopy analysis method (HAM) is applied to obtain the approximate traveling wave solutions of the coupled Whitham-Broer-Kaup (WBK) equations in shallow water. Comparisons are made between the results of the proposed method and exact solutions. The results show that the homotopy analysis method is an attractive method in solving the systems of nonlinear partial differential equations

    Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments

    Get PDF
    BACKGROUND: Multiple sclerosis (MS) is a highly debilitating immune mediated disorder and the second most common cause of neurological disability in young and middle-aged adults. Iran is amongst high MS prevalence countries (50/100,000). Economic burden of MS is a topic of important deliberation in economic evaluations study. Therefore determining of cost-effectiveness interferon beta (INF β) and their copied biopharmaceuticals (CBPs) and biosimilars products is significant issue for assessment of affordability in Lower-middle-income countries (LMICs). METHODS: A literature-based Markov model was developed to assess the cost-effectiveness of three INF βs products compared with placebo for managing a hypothetical cohort of patients diagnosed with relapsing remitting MS (RRMS) in Iran from a societal perspective. Health states were based on the Kurtzke Expanded Disability Status Scale (EDSS). Disease progression transition probabilities for symptom management and INF β therapies were obtained from natural history studies and multicenter randomized controlled trials and their long term follow up for RRMS and secondary progressive MS (SPMS). A cross sectional study has been developed to evaluate cost and utility. Transitions among health states occurred in 2-years cycles for fifteen cycles and switching to other therapies was allowed. Calculations of costs and utilities were established by attachment of decision trees to the overall model. The incremental cost effectiveness ratio (ICER) of cost/quality adjusted life year (QALY) for all available INF β products (brands, biosimilars and CBPs) were considered. Both costs and utilities were discounted. Sensitivity analyses were done to assess robustness of model. RESULTS: ICER for Avonex, Rebif and Betaferon was 18712, 11832, 15768 US Dollars ()respectivelywhenutilityattainedfromliteraturereviewhasbeenconsidered.ICERforavailableCBPsandbiosimilarsinIranwas) respectively when utility attained from literature review has been considered. ICER for available CBPs and biosimilars in Iran was 847, 6964and6964 and 11913. CONCLUSIONS: The Markov pharmacoeconomics model determined that according to suggested threshold for developing countries by world health organization, all brand INF β products are cost effective in Iran except Avonex. The best strategy among INF β therapies is CBP intramuscular INF β-1a (Cinnovex). Results showed that a policy of encouraging accessibility to CBPs and biosimilars could make even high technology products cost-effective in LMICs
    • …
    corecore